Orchid Chem, STADA Pharma sign dealOur Web Bureau / Mumbai March 16, 2005Orchid Chemicals & Pharmaceuticals (Orchid) today announced that it has entered into an exclusive agreement with STADA Pharmaceuticals (STADA), the U.S. subsidiary of STADA Arzneimittel AG, for the development and supply of six prescription generic drug products to STADA for the US market. According to a release issued by Orchid to the BSE, these non-cephalosporin formulations would cover diverse therapeutic segments including cardio-vascular, central nervous system, anti-allergic, gastrointestinal and anti-infective categories. The release said that the current market size of the products in US aggregates to around $12.5 billion, and Orchid would commence supply of these products once they go off-patent progressively from 2007 onward based on company
